Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors
Rebekka Duhen, Olivier Fesneau, Kimberly A. Samson, Alexandra K. Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D. Weinberg, Thomas Duhen
Rebekka Duhen, Olivier Fesneau, Kimberly A. Samson, Alexandra K. Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D. Weinberg, Thomas Duhen
View: Text | PDF
Research Article Immunology Oncology

PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors

  • Text
  • PDF
Abstract

CD4+ Th cells play a key role in orchestrating immune responses, but the identity of the CD4+ Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4+ Th cells distinct from FOXP3+ Tregs that coexpressed programmed cell death 1 (PD-1) and ICOS. These tumor-infiltrating lymphocyte CD4+ Th cells (CD4+ Th TILs) had a tissue-resident memory phenotype, were present in MHC class II–rich areas, and proliferated in the tumor, suggesting local antigen recognition. The T cell receptor repertoire of the PD-1+ICOS+ CD4+ Th TILs was oligoclonal, with T cell clones expanded in the tumor, but present at low frequencies in the periphery. Finally, these PD-1+ICOS+ CD4+ Th TILs were shown to recognize both tumor-associated antigens and tumor-specific neoantigens. Our findings provide an approach for isolating tumor-reactive CD4+ Th TILs directly ex vivo that will help define their role in the antitumor immune response and potentially improve future adoptive T cell therapy approaches.

Authors

Rebekka Duhen, Olivier Fesneau, Kimberly A. Samson, Alexandra K. Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D. Weinberg, Thomas Duhen

×

Figure 7

DP CD4+ Th TILs recognize HPV-associated antigens.

Options: View larger image (or click on image) Download as PowerPoint
DP CD4+ Th TILs recognize HPV-associated antigens.
(A) In vitro–expanded...
(A) In vitro–expanded CD4+ TIL subsets (DN, SP, and DP) were cocultured with autologous B cells pulsed with DMSO or the indicated peptide pools. T cell reactivity was assessed by OX40 upregulation after 24 hours of culturing. Data for 1 representative patient with HPV+ HNSCC are shown. (B) Summary of the reactivity of CD4+ Th subsets to the indicated peptide pools for 6 patients with HPV+ HNSCC. (C) Summary of the reactivity of CD8+ T cells to HPV16 E6, HPV16 E7, and CEFX peptide pools for the same 6 patients with HPV+ HNSCC. CD8+ T cell activation was assessed by 4-1BB upregulation. DP CD4+ (D) and DP CD8+ (E) TILs isolated from 1 patient with HPV+ HNSCC were cultured with autologous B cells pulsed with DMSO, the HPV16 E6 peptide pool, or the individual overlapping peptides contained in the HPV16 E6 peptide pool (n = 37). Reactivity was measured by IFN-γ ELISPOT assay. SEB or anti-CD3 antibodies were used as positive controls for CD4+ and CD8+ T cells, respectively. (F) Summary of the reactivity of DP CD4+ and DP CD8+ TILs to HPV16 E6 individual peptides for 3 different patients with HPV+ HNSCC, as measured by IFN-γ ELISPOT assay. The colors in the heatmap legend represent the number of detected spots/105 cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts